Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
BUSINESS Takeda Taps Asuka Miyabashira as New Japan Pharma Chief
March 14, 2024
-
REGULATORY Disclosure Guidelines on Generic Supply Info Up for Public Comments
March 13, 2024
-
BUSINESS Novo Gears Up Sustainability Efforts by Recycling Injectors in Japan
March 13, 2024
-
REGULATORY Japan Needs Systemic Reform to Balance Universal Coverage and Access to Pricey Meds: LDP Health Affairs Chief
March 13, 2024
-
BUSINESS Full Resumption of Quake-Hit Santen Plant Delayed into April
March 13, 2024
-
REGULATORY English Versions of MHLW Biosimilar Trial Guidance, Q&As Now Available
March 13, 2024
-
COMMENTARY With So Many of Its Demands Met, How Will Industry Oppose Off-Year Price Revisions in FY2025?
March 12, 2024
-
ACADEMIA Pediatric Specialist Pins Hope on Efficacy of Pfizer’s RSV Shot in Healthy Infants
March 12, 2024
-
BUSINESS Amgen’s Otezla Hits Primary Goal in PIII of Japanese PPP Patients
March 12, 2024
-
BUSINESS Towa Develops Analytical Method for Nitrosamine in Antidepressant Duloxetine
March 12, 2024
-
BUSINESS Sosei, Boehringer Ingelheim Join Hands in Schizophrenia Treatment
March 12, 2024
-
BUSINESS Ono Forges Comprehensive Research Alliance with Harvard
March 12, 2024
-
BUSINESS Genmab Files Epkinly for Follicular Lymphoma Grade 1-3A in Japan
March 12, 2024
-
REGULATORY Japan to Simplify Screening for Third-Party Use of Highly Anonymous NDB Data
March 11, 2024
-
REGULATORY Consolidate IRBs to Streamline Clinical Trials in Japan: Govt Working Group
March 11, 2024
-
REGULATORY Japanese Health Minister Cautions Public on Multiple Measles Outbreaks
March 11, 2024
-
REGULATORY PMDA Looks to Rev Up Pediatric and Orphan Drug Initiatives in Next 5-Year Plan: Chief
March 11, 2024
-
BUSINESS Xolair SC Pen Versions Approved in Japan: Novartis
March 11, 2024
-
ACADEMIA Expert Says RSV Shots Will Have Significant Clinical Impact, Urges Public Funding and NIP Inclusion
March 8, 2024
-
BUSINESS Eisai CEO Confident in Leqembi Uptake, Says 90% of US Hospital Targets to Adopt Med by March-End
March 8, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…